ThermoGenesis Announces Shelf Registration Is Declared Effective

RANCHO CORDOVA, Calif., Dec. 14 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. previously filed a shelf registration statement with the Securities and Exchange Commission ("SEC") registering an indeterminate number of shares of common stock that may be used in the future in one or more financings. The registration statement has been declared effective by the SEC. The Company will file a supplement to the prospectus prior to any sale or issuance of the common stock.

Philip Coelho, Chairman and CEO, noted that, "The Company has greatly expanded its product offerings and partnership alliances in recent periods. The markets we are in are both quickly evolving and/or rapidly expanding. These dynamics are exciting and provide opportunities that require a timely response. The intent of the registration statement is simply to position the Company with the required timely flexibility over the next three years to further our strategic objectives. Along with other strategic possibilities, we will be assessing the product development needs of both our new distribution partners and the Principal Investigators of cell therapy clinical trials with the goal of expanding our enabling technologies to provide value in the new cell therapy market." Noting that a shelf registration statement allows, but does not require, the Company to use the shares registered over a three-year period, Coelho further stated that, "The Company's shareholders have recently approved an additional thirty million common shares and, while the Company will be evaluating its resource needs in relation to its business and strategic relationships and opportunities, there are no immediate plans for the majority of the recently approved shares, including financings. The Company will continue to monitor market conditions to assess any future use of the approved shares."

About ThermoGenesis Corp.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood.

* The BioArchive(R) System, an automated robotic cryogenic device, is used by major cord blood stem cell banks in 26 countries as a key enabling technology for cryopreserving and archiving cord blood stem cell units for transplant. * The AutoXpress(TM) System, currently undergoing testing, is a semi- automated robotic device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood. Product launch is expected in early 2006. * The CryoSeal(R) FS System, a semi-automated device and companion sterile blood processing disposable, is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. Enrollment in a 150 patient U.S. pivotal clinical trial has been completed and a PMA is being prepared. The CryoSeal FS System has been CE marked since 2001. It is sold in Europe and nine additional countries. * The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of patient blood, or blood plasma in 25 minutes. The TPD is CE marked and was introduced in Europe in the summer of 2005.

The statements contained in this release which are not historical facts are

forward-looking statements that are subject to risks and uncertainties that

could cause actual results to differ materially from those expressed in the

forward-looking statements, including, but not limited to, certain delays

beyond the Company's control with respect to market acceptance of new

technologies and products, delays in testing and evaluation of products, and

other risks detailed from time to time in the Company's filings with the

Securities and Exchange Commission.

CONTACT: Matt Plavan of ThermoGenesis Corp., +1-916-858-5100

Web site: http://www.thermogenesis.com/